NDAORALTABLET
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
JENTADUETO (linagliptin and metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JENTADUETO is a fixed-dose combination oral tablet containing linagliptin (a DPP-4 inhibitor) and metformin hydrochloride, approved by the FDA on January 30, 2012. It is indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. The product works by inhibiting dipeptidyl peptidase 4, thereby increasing incretin levels and reducing blood glucose in a glucose-dependent manner, while metformin reduces hepatic glucose production and improves insulin sensitivity. JENTADUETO serves as a convenient dual-mechanism combination therapy for patients requiring both agents.
$0.1BPart D
11.6 years to LOEMechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.
Started Nov 2013
36 enrolled
Healthy
Career Relevance
JENTADUETO supports endocrinology-focused brand management, medical science liaison (MSL), and field sales roles within Boehringer Ingelheim's diabetes franchise, particularly among primary care and endocrinology specialists. Key skills for this product include knowledge of type 2 diabetes management algorithms, competitive positioning versus GLP-1 and SGLT2 inhibitor classes, and patient compliance strategies for combination therapy. Currently, zero open job positions are linked to this product, reflecting its mature market status and stable team structure.
Worked on JENTADUETO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.